ZYPREXA RELPREVV
LOE Approachingolanzapine pamoate
NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Dec 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPREXA RELPREVV is an extended-release intramuscular suspension formulation of olanzapine pamoate, an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It delivers sustained therapeutic levels over weeks, improving medication adherence compared to oral formulations.
$0.004BPart D
LOE ApproachingProduct is approaching loss of exclusivity with modest Part D utilization, indicating a mature, niche market with likely declining team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Started Apr 2006
524 enrolled
Schizophrenia
Career Relevance
ZYPREXA RELPREVV currently has no linked job postings, indicating limited active hiring around this product. Career opportunities are likely minimal as the product matures toward generic competition.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.